Repatha vs Brilinta
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Repatha | US Brilinta | |
|---|---|---|
| Generic name | evolocumab | ticagrelor |
| Drug class | PCSK9 Inhibitor (Biologic) | P2Y12 Platelet Inhibitor (Antiplatelet) |
| Treats | High cholesterol, cardiovascular disease | Acute coronary syndrome, heart attack prevention |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Amgen | AstraZeneca |
| Year approved | 2015 | 2011 |
| FDA warning | No boxed warning | Black box warning |
| Est. TV ad spend | $120M | $120M |
| Common side effects | Injection site reactions, Allergic reactions, Back pain, Fatigue | Bleeding, Shortness of breath, Bruising, Headache |
Frequently asked questions
Is Repatha or Brilinta better?
Neither is universally "better." Repatha (evolocumab) and Brilinta (ticagrelor) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Repatha and Brilinta?
Repatha is a PCSK9 Inhibitor (Biologic) made by Amgen, while Brilinta is a P2Y12 Platelet Inhibitor (Antiplatelet) made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Repatha has the larger estimated TV advertising budget of the two.